Call Us: (513) 621-5112

 
 
 
 
 
 
Sterling Research Blog
 
Contrave Approved by the FDA for Weight Loss
Friday, September 12, 2014

These are exciting days in the world of Clinical Research. On September 10th Contrave, a medication we are actively studying at Sterling Research, was approved by the FDA for weight loss. It is always satisfying when a study medication makes it to the market. Now, millions of people may benefit from Contrave. This accomplishment would not have been attained without the help of study volunteers. I commend all of the Medical Heroes that participate in Clinical Trials!

-Dr. Wenker




 
 
Subscribe To Our Blog

Blog Categories

  • Articles
  • News
    • 09/08/2017 - Gout Increasingly Common Among
    • 06/09/2017 - Understanding Fatty Liver
    • 03/28/2016 - Acne: More Than Just Pimples
    • 08/11/2015 - It's Coming...You Know It Is..
    • 02/10/2015 - Attorney General's Office Dema
    • 10/16/2014 - Regeneron, Sanofi drug slashes
    • 10/10/2014 - Ongoing Ebola Epidemic
    • 09/12/2014 - Contrave Approved by the FDA f
    • 07/11/2014 - Saxenda Recommended for Approv
    • 09/04/2013 - Only Half of Hypertensive Adul

Tag Cloud
 
 
 

CONTACT US
NEWS & ARTICLES
Call For Participation
Patient Recruitment Specialist
Cincinnati, OH

PH: (513) 621-5112
FX:  (513) 621-5101

Cincinnati / Mt. Auburn
2230 Auburn Avenue
Level B
Cincinnati, OH 45219
PH: (513) 381-4100
FX:  (513) 381-4120

Springdale
375 Glensprings Drive
2nd Floor
Cincinnati, OH 45246
PH: (513) 671-8080
FX:  (513) 671-8090
Gout Increasingly Common Among Americans
Friday, September 8, 2017

Gout is a type of arthritis with both acute and chronic features. The problem is caused by too much uric acid in your blood stream. An acute flare occurs when the excess uric acid forms into crystals which deposit in a joint like your wrist, knee, ankle or most commonly the big toe.

 
 
 



Copyright © 2017. STERLING RESEARCH. All Rights Reserved